PubRank

Jason B Fleming

Author PubWeight™ 136.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008 15.05
2 Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013 6.53
3 Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009 3.36
4 Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008 3.36
5 Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009 3.22
6 LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008 2.99
7 KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012 2.55
8 ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 2011 2.49
9 Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011 2.24
10 Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol 2011 2.23
11 Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007 2.19
12 Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement. Ann Surg Oncol 2012 2.08
13 Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012 2.01
14 Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 2011 1.64
15 Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 2008 1.61
16 Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). J Cell Biochem 2014 1.55
17 Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors. AJR Am J Roentgenol 2012 1.47
18 Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 2010 1.38
19 Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer 2011 1.32
20 Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 2010 1.28
21 Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest 2014 1.26
22 Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol 2008 1.26
23 Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2011 1.24
24 Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg 2005 1.23
25 Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am 2012 1.23
26 Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol 2011 1.23
27 High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2010 1.23
28 Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol 2012 1.18
29 Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin 2008 1.16
30 A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology 2013 1.15
31 Current diagnosis and management of unusual pancreatic tumors. Am J Surg 2008 1.15
32 Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. Clin Cancer Res 2002 1.13
33 Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg 2008 1.12
34 Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford) 2012 1.09
35 Role of EUS-FNA-based cytology in the diagnosis of mucinous pancreatic cystic lesions: a systematic review and meta-analysis. Dig Dis Sci 2010 1.08
36 K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol Cancer Res 2009 1.06
37 Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2014 1.06
38 Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 2011 1.03
39 TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation. Cancer Res 2009 1.02
40 Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg 2012 1.01
41 Diagnosis and management of cystic neoplasms of the pancreas: an evidence-based approach. J Am Coll Surg 2008 1.00
42 Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter. Proc Natl Acad Sci U S A 2010 1.00
43 Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 2006 0.99
44 Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin Cancer Res 2013 0.98
45 Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg 2013 0.98
46 Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg 2012 0.98
47 Surgical therapy of peptic ulcers in the 21st century: more common than you think. Am J Surg 2005 0.98
48 Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer. Arch Surg 2012 0.98
49 Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Ann Surg Oncol 2013 0.97
50 Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. HPB (Oxford) 2012 0.96
51 Intravenous delivery of the plasma fraction of stored packed erythrocytes promotes pancreatic cancer growth in immunocompetent mice. Cancer 2010 0.96
52 Multidisciplinary management strategy for incidental cystic lesions of the pancreas. J Am Coll Surg 2010 0.95
53 A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg 2012 0.94
54 Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol 2014 0.94
55 Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: single-center experience with 79 cases. Dig Dis Sci 2011 0.94
56 Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer. J Surg Oncol 2014 0.94
57 Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. Ann Surg Oncol 2006 0.93
58 Current status of adjuvant therapy for pancreatic cancer. Oncologist 2010 0.93
59 Pancreatic Schwannoma presenting as a cystic lesion. Gastrointest Endosc 2009 0.93
60 The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol 2013 0.93
61 Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2011 0.93
62 Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol 2012 0.93
63 Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol 2011 0.92
64 Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg 2013 0.90
65 Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol 2013 0.88
66 Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution. Am J Surg Pathol 2014 0.87
67 High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res 2010 0.87
68 Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol 2012 0.87
69 Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2012 0.86
70 Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells. Histopathology 2012 0.86
71 Ninety-day Postoperative Mortality Is a Legitimate Measure of Hepatopancreatobiliary Surgical Quality. Ann Surg 2015 0.86
72 The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. Arch Pathol Lab Med 2013 0.85
73 The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma. Ann Surg Oncol 2014 0.85
74 Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Am J Surg Pathol 2015 0.84
75 The fallen one: the inferior parathyroid gland that descends into the mediastinum. J Am Coll Surg 2009 0.84
76 Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. Ann Surg Oncol 2011 0.84
77 Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg 2013 0.83
78 Challenges in the study of adjuvant chemoradiation after pancreaticoduodenectomy. Ann Surg Oncol 2010 0.83
79 Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Ann Surg Oncol 2014 0.83
80 Distal pancreatectomy for isolated metastasis of endometrial carcinoma to the pancreas. JOP 2008 0.83
81 Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) 2013 0.82
82 Endoscopic management of duodenal adenomas in familial adenomatous polyposis--a single-center experience. Dig Dis Sci 2011 0.81
83 Pancreatic neuroendocrine neoplasms: diagnosis and management. Abdom Imaging 2013 0.81
84 Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT. Gastrointest Endosc 2013 0.81
85 Combined esophagectomy and pancreaticoduodenectomy: expanded indication for supercharged jejunal interposition. J Gastrointest Surg 2011 0.81
86 Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol 2012 0.81
87 Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors. Ann Surg Oncol 2012 0.81
88 Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol 2014 0.81
89 A focused curriculum in surgical oncology for the third-year medical students. J Surg Res 2013 0.81
90 Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology 2013 0.80
91 Study human pancreatic cancer in mice: how close are they? Biochim Biophys Acta 2012 0.80
92 Feasibility study of EUS-NOTES as a novel approach for pancreatic cancer staging and therapy: an international collaborative study. Hepatogastroenterology 2013 0.79
93 After Pancreatectomy, the “90 Days from Surgery” Definition Is Superior to the “30 Days from Discharge” Definition for Capture of Clinically Relevant Readmissions. J Gastrointest Surg 2016 0.79
94 Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. Am J Surg Pathol 2016 0.79
95 Diagnostic yield of endoscopic retrograde cholangiopancreatography-based cytology for distinguishing malignant and benign intraductal papillary mucinous neoplasm: systematic review and meta-analysis. Dig Endosc 2014 0.78
96 Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol 2013 0.78
97 Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol 2015 0.78
98 Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg 2013 0.78
99 Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients. HPB (Oxford) 2013 0.77
100 Serum brain naturietic peptide measurements reflect fluid balance after pancreatectomy. J Am Coll Surg 2012 0.77
101 Focal adhesions and associated proteins in medullary thyroid carcinoma cells. J Surg Res 2003 0.77
102 Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg 2012 0.77
103 Is endoscopic ultrasound "sound" for pancreatic cancer screening? J Clin Gastroenterol 2009 0.76
104 The recognition and surgical management of heritable lesions of the pancreas. Surg Oncol Clin N Am 2009 0.76
105 Metastatic adult granulosa cell tumor mimicking a benign pancreatic cyst. Ann Diagn Pathol 2010 0.76
106 MicroRNA dissects out dangerous pancreatic cysts from all the rest. Clin Cancer Res 2012 0.76
107 Prevalence of extra-pancreatic cysts in patients with cystic pancreatic lesions detected by endoscopic ultrasound. Endosc Ultrasound 2015 0.75
108 Laparoscopic choledochojejunostomy via PTFE-covered stent successfully achieves internal drainage of common bile duct obstruction. HPB (Oxford) 2005 0.75
109 Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. Am J Surg Pathol 2017 0.75
110 Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach: A Population-based Analysis. Ann Surg 2016 0.75
111 MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell 2017 0.75
112 Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas 2017 0.75